Bioinspired vaccines to enhance MHC class-I antigen cross-presentation

Curr Opin Immunol. 2022 Aug:77:102215. doi: 10.1016/j.coi.2022.102215. Epub 2022 Jun 4.

Abstract

Cross-presentation of exogenous antigen on MHC class-I is a crucial process for generating a CD8+ T cell response, and is therefore an important design consideration in the development of T-cell-engaging vaccines against viruses, intracellular bacteria, and cancers. Here, we briefly summarize known cross-presentation pathways and highlight how synthetic vaccines can be engineered to enhance MHC-I presentation of exogenous peptide and protein antigens by professional antigen-presenting cells (APCs). In particular, we summarize how molecular engineering and nanotechnology are being harnessed to enhance antigen delivery to lymph nodes and to cross-presenting dendritic cells, to bypass endosomal trafficking of exogenous antigen to promote delivery of antigen to the cytosol of APCs, and to coordinate the delivery of antigen with immune-stimulating adjuvants that can act synergistically to augment antigen cross-presentation.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adjuvants, Immunologic
  • Antigen Presentation
  • Antigens
  • CD8-Positive T-Lymphocytes
  • Cross-Priming*
  • Dendritic Cells
  • Histocompatibility Antigens Class I
  • Humans
  • Vaccines*

Substances

  • Adjuvants, Immunologic
  • Antigens
  • Histocompatibility Antigens Class I
  • Vaccines